letrozole and fulvestrant

letrozole has been researched along with fulvestrant in 93 studies

Research

Studies (93)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (4.30)18.2507
2000's25 (26.88)29.6817
2010's46 (49.46)24.3611
2020's18 (19.35)2.80

Authors

AuthorsStudies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, JZ; Khan, MZI; Nazli, A; Uzair, M1
Dickson, RB; El-Ashry, D; Hannum, RS; Kern, FG; Kharbanda, S; Lopez, CA; Lorant, LA; McLeskey, SW; Tobias, CA; Trock, BJ; Zhang, L1
Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, J; Yue, W1
Brodie, AM; Grigoryev, DN; Long, BJ; Thiantanawat, A; Tilghman, SL; Yue, W1
Brodie, A; Gimbel, M; Grigoryev, D; Liu, Y; Long, BJ; Lu, Q1
Mokbel, K1
Tominaga, T1
Brodie, AM; Jelovac, D; Long, BJ; Thiantanawat, A1
Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I1
Eckhardt, S1
Tobias, JS1
Harwood, KV1
Brodie, A; Goloubeva, O; Jelovac, D; Macedo, L; Sabnis, G; Tilghman, S1
Kaplow, R1
Dodwell, D; Vergote, I1
Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Macedo, L1
Brodie, A; Goloubeva, O; Jelovac, D; Long, B; Macedo, L; Sabnis, G1
Connell, BJ; Cribb, AE; Legge, C; Saleh, TM1
Chagin, AS; Chrysis, D; Ritzen, EM; Sävendahl, L; Takigawa, M1
DiLeonardo, M; Gibbons, G; Resnik, KS1
Brodie, A; Jelovac, D; Sabnis, G1
Croxatto, HB; Garfield, R; Ortiz, ME; Ortiz, RE; Zepeda, AJ1
Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR1
Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M1
Chen, S; Lui, K; Mori, T; Tamura, T; Zhou, D1
Bütow, A; Fester, L; Huber, C; Jarry, H; Prange-Kiel, J; Rune, GM; von Lossow, R; Zhou, L1
Bonthuis, P; Ding, A; Park, JH; Rais, S; Rissman, EF1
Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P1
Dieni, C; Frondaroli, A; Grassi, S; Pettorossi, VE; Scarduzio, M1
Bocchinfuso, W; Conaway, M; Fan, P; Korach, KS; Li, Y; Liu, G; Santen, R; Wang, H; Wang, JP; Yue, W; Zhang, N1
Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T1
Brodie, A; Carboni, JM; Finckenstein, FG; Gottardis, MM; Greer, A; Haluska, P; Harrington, SC; Hou, X; Huang, F; Macedo, LF; Reeves, KA1
Bois, C; Bouraïma-Lelong, H; Carreau, S; Delalande, C; Durand, P1
Chen, S; Reddy, K; Smith, D; Wang, X; Wong, C1
Li, W; Tang, L; Wu, L; Xiong, Y; Zhou, X1
Berger, T; Conley, AJ; Hovey, RC; Roser, JF; Van Klompenberg, M1
Dowsett, M; Gao, Q; Isacke, CM; Mackay, A; Martin, LA; Morandi, A; Pancholi, S; Plaza-Menacho, I; Robertson, D; Zvelebil, M1
Mehta, A; Tripathy, D1
Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I1
Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW1
Aktas, B; Anton, A; Carrasco, E; De la Haba-Rodriguez, JR; Garcia-Saenz, JÁ; Gil, M; Guerrero, A; Liedtke, C; Loibl, S; Margeli, M; Martín, M; Martinez, N; Mehta, K; Morales, S; Muñoz, M; Ramos, M; Schoenegg, W; von Minckwitz, G; Wachsmann, G1
Berger, T; Conley, AJ; Katleba, KD; Legacki, EL1
Cheng, J; Hong, Q; Jia, X; Lei, L; Li, D; Li, J; Liu, G; Mo, M; Shao, Z; Shen, Z; Wang, Y1
Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R1
Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I1
Tamura, K1
Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M1
Batson, S; Jones, N; Livings, C; Telford, C1
Gilarranz, YJ; Lopez-Tarruella, S; Martin, M1
Niraula, S; Ocana, A1
Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C1
Endo, T; Hasegawa, K; Higashi, Y; Kamiya, A; Kaneko, J; Kondo, I; Maejima, S; Takatsuno, Y1
Cappelletti, MR; Corona, SP; Cretella, D; Dester, M; Generali, D; Gobbi, A; Petronini, PG; Ravelli, A; Zanotti, L1
Dalmau, E; Fernández-Morales, LA; Marín, M; Martinez Vila, C; Oliveres, H; Pardo, JC; Ribera, P; Segui, MA1
Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D1
Kim, ES; Scott, LJ1
Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B1
He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S1
Messina, C; Messina, M; Zanardi, E1
Freedman, RA; Tolaney, SM1
Bartlett, CH; Colleoni, M; Cristofanilli, M; DeMichele, A; Diéras, V; Ettl, J; Finn, RS; Gelmon, KA; Giorgetti, C; Im, SA; Iyer, S; Lipatov, O; Lu, DR; Martin, M; Mori, A; Moulder, S; Turner, NC1
Chen, L; Ding, W; Li, Z; Ruan, G; Tu, C; Wang, C1
Colleoni, M; Cristofanilli, M; Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Huang Bartlett, C; Loi, S; Lu, DR; Mori, A; Rugo, HS; Schnell, P; Slamon, DJ; Turner, NC1
Bartlett, CH; Finn, RS; Harbeck, N; Huang, X; Im, SA; Iyer, S; Johnston, S; Joy, AA; Kim, S; Masuda, N; Rugo, HS; Schnell, P; Sun, W; Turner, NC; Verma, S1
Band, J; Darden, C; Davis, K; Iyer, S; McSorley, D; Mitra, D1
Darbre, PD; Williams, GP1
Abraham, J; Budd, GT; Eziokwu, AS; Jia, X; Kruse, M; Montero, AJ; Moore, HCF; Varella, L1
Chen, Q; Dai, Y; Guo, Q; Lin, X; Xu, R; Ye, L; Zhang, Y1
Berger, T; Kucera, H; Sidhu, P; Tang, S1
Aktas, B; Barry, WT; Carey, LA; Carrasco, E; Casas, M; Cirrincione, CT; De la Haba-Rodríguez, J; Dickler, MN; Furlanetto, J; Garcia-Saenz, JA; Guerrero-Zotano, A; Hahn, O; Hudis, C; Hyslop, T; Loibl, S; Martín, M; Martinez-Jañez, N; Mehta, K; Morales, S; Partridge, A; Rodriguez-Martin, C; Winer, E1
Yardley, DA1
Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S1
Cho, YU; Ham, A; Kim, GM; Kim, JH; Kim, JY; Kim, MH; Kim, SI; Park, BW; Park, HS; Park, S; Sohn, J1
Bergqvist, M; Bethune, A; Bidard, FC; Brain, E; Cabel, L; Cottu, P; Donnadieu, A; Kiavue, N; Lerebours, F; Loirat, D; Pierga, JY; Rodrigues, M; Rosenblum, D; Tanguy, ML1
Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mukai, H; Muramatsu, Y; Ohno, S; Ohtani, S; Rai, Y; Shimizu, C; Toi, M; Umeyama, Y1
Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M1
André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK1
Arnaud, A; Debourdeau, P; Grenier, J; Vazquez, L1
Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil-Gil, M; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-de Dueñas, E; Pérez-García, JM; Ruíz-Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P1
Fu, F; Guindy, M; Kano, J; Ma, J1
Jacobson, A1
Çelik, H; Çil, T; Duman, BB; Erçolak, V; Eser, K; İnal, A; Kesen, O; Köşeci, T; Önder, AH; Öztürk, B; Sezer, E1
Adam, JP; Chabot, I; David, MÈ; Lessard-Hurtubise, R; Marineau, A; St-Pierre, C1
Attwood, K; Edge, S; Hamilton, D; Knudsen, ES; Levine, E; O'Connor, T; Schultz, E; Witkiewicz, AK1
Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P1
Choong, GM; Ferre, RAL; Giridhar, KV; Goetz, MP; Haddad, TC; Hobday, TJ; Liddell, S; Liu, MC; O'Sullivan, CC; Peethambaram, PP; Ruddy, KJ1
Acconcia, F1
Aguirre, E; Albanell, J; Amillano, K; Bellet, M; Carañana, V; Cortés, J; Dalenc, F; Di Cosimo, S; Gavilá, J; Gil Gil, MJ; Gligorov, J; Llombart-Cussac, A; Malfettone, A; Marmé, F; Martínez-De Dueñas, E; Mina, L; Pérez-García, JM; Ruiz Borrego, M; Sampayo-Cordero, M; Schmid, P; Schneeweiss, A; Wheatley, D; Zamora, P1
Ademuyiwa, FO; Clifton, K; Dai, C; Davis, AA; Dong, X; Du, P; Frith, A; Haas, B; Hernandez-Aya, LF; Jia, S; King, BL; Krishnamurthy, J; Luo, J; Luo, SJ; Ma, CX; Peterson, LL; Rearden, TP; Rigden, C; Summa, T; Suresh, R; Tan, L; Tandra, PK; Thomas, S; Wang, X; Weilbaecher, K; Zheng, T; Zhou, K1

Reviews

31 review(s) available for letrozole and fulvestrant

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
An overview on Estrogen receptors signaling and its ligands in breast cancer.
    European journal of medicinal chemistry, 2022, Nov-05, Volume: 241

    Topics: Breast Neoplasms; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ligands; Male; Receptors, Estrogen

2022
[Developments of hormonal agents for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:7

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles

2001
[Perspectives for the hormonal therapy of breast cancer].
    Magyar onkologia, 2003, Volume: 47, Issue:2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles

2003
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
    The international journal of biochemistry & cell biology, 2004, Volume: 36, Issue:11

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles

2004
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
    Clinical journal of oncology nursing, 2004, Volume: 8, Issue:6

    Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles

2004
Therapeutic observations in MCF-7 aromatase xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Nitriles; Receptors, Estrogen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2005
Innovations in antineoplastic therapy.
    The Nursing clinics of North America, 2005, Volume: 40, Issue:1

    Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate

2005
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Cancer treatment reviews, 2005, Volume: 31, Issue:4

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2005
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
    Ugeskrift for laeger, 2007, Sep-10, Volume: 169, Issue:37

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2007
Management of patients with metastatic breast cancer.
    Advances in therapy, 2011, Volume: 28 Suppl 6

    Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles

2011
AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
    Breast cancer research and treatment, 2012, Volume: 134, Issue:2

    Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Letrozole; Nitriles; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Transcriptional Activation; Triazoles

2012
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1

    Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles

2014
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
    The Annals of pharmacotherapy, 2015, Volume: 49, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles; United States

2015
Development of cell-cycle checkpoint therapy for solid tumors.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Aurora Kinase A; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Proliferation; Clinical Trials as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Letrozole; Molecular Targeted Therapy; Neoplasm Staging; Nitriles; Nuclear Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Estrogen; Triazoles

2015
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
    Clinical breast cancer, 2016, Volume: 16, Issue:3

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles

2016
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
    Breast (Edinburgh, Scotland), 2016, Volume: 28

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2016
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
    Cancer treatment reviews, 2016, Volume: 50

    Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles

2016
CDK4/6 inhibitors in HER2-positive breast cancer.
    Critical reviews in oncology/hematology, 2017, Volume: 112

    Topics: Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Fulvestrant; Humans; Letrozole; Molecular Targeted Therapy; Nitriles; Protein Kinase Inhibitors; Receptor, ErbB-2; Triazoles

2017
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
    Current medical research and opinion, 2017, Volume: 33, Issue:8

    Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles

2017
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
    Targeted oncology, 2017, Volume: 12, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Triazoles

2017
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Current medical research and opinion, 2017, Volume: 33, Issue:9

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles

2017
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
    Medicine, 2017, Volume: 96, Issue:33

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles

2017
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 12-01, Volume: 28, Issue:12

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles

2017
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
    Breast cancer research and treatment, 2018, Volume: 167, Issue:3

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles

2018
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis.
    Medicine, 2018, Volume: 97, Issue:20

    Topics: Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome; Triazoles

2018
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 101

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen

2018
Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Targeted oncology, 2019, Volume: 14, Issue:2

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Piperazines; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    The Lancet. Oncology, 2019, Volume: 20, Issue:10

    Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2019
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
    European journal of clinical investigation, 2021, Volume: 51, Issue:7

    Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab

2021
[Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?]
    Bulletin du cancer, 2021, Volume: 108, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Male; Middle Aged; Multivariate Analysis; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies; Thrombocytopenia

2021

Trials

10 trial(s) available for letrozole and fulvestrant

ArticleYear
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
    Breast cancer research and treatment, 2003, Volume: 79, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles

2003
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-20, Volume: 33, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Germany; Hormones; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Spain; Treatment Outcome; Triazoles; Vascular Endothelial Growth Factor A

2015
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 03-01, Volume: 29, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Progression-Free Survival; Pyridines; Quality of Life; Viscera

2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
    Journal of the National Cancer Institute, 2019, 04-01, Volume: 111, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen

2019
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 117

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Evaluation Studies as Topic; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Tamoxifen

2019
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
    Future oncology (London, England), 2019, Volume: 15, Issue:23

    Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult

2019
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
    Breast cancer (Tokyo, Japan), 2021, Volume: 28, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Japan; Letrozole; Middle Aged; Piperazines; Postmenopause; Premenopause; Progression-Free Survival; Pyridines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen

2021
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
    Cancer science, 2021, Volume: 112, Issue:6

    Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome

2021
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
    JAMA oncology, 2021, 12-01, Volume: 7, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Piperazines; Pyridines; Receptor, ErbB-2

2021
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
    The oncologist, 2023, 01-18, Volume: 28, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Pulmonary Embolism; Receptor, ErbB-2; Receptors, Estrogen; Venous Thromboembolism

2023

Other Studies

52 other study(ies) available for letrozole and fulvestrant

ArticleYear
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:3

    Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line; Chloramphenicol O-Acetyltransferase; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Humans; Letrozole; Luciferases; Mice; Mice, Nude; Nitriles; Ovariectomy; Polymerase Chain Reaction; Receptors, Progesterone; Recombinant Fusion Proteins; RNA, Messenger; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured

1998
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
    Breast cancer research and treatment, 1998, Volume: 50, Issue:1

    Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured

1998
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
    The Journal of steroid biochemistry and molecular biology, 1998, Volume: 67, Issue:4

    Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Division; Cells, Cultured; Choriocarcinoma; DNA Primers; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblasts; Fulvestrant; Humans; Letrozole; Microsomes; Nitriles; Placenta; RNA, Messenger; Triazoles; Tumor Cells, Cultured

1998
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Breast cancer research and treatment, 1999, Volume: 57, Issue:2

    Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Tamoxifen; Time Factors; Triazoles; Tumor Cells, Cultured

1999
The Twenty-third Annual San Antonio Breast Cancer Symposium.
    Current medical research and opinion, 2001, Volume: 16, Issue:4

    Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2001
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:7

    Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles; Tumor Cells, Cultured

2002
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Cancer research, 2005, Jun-15, Volume: 65, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays

2005
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    The Journal of steroid biochemistry and molecular biology, 2005, Volume: 95, Issue:1-5

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; GRB2 Adaptor Protein; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Models, Biological; Nitriles; Receptors, Estrogen; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2005
Estrogen synthesis in the central nucleus of the amygdala following middle cerebral artery occlusion: role in modulating neurotransmission.
    Neuroscience, 2005, Volume: 135, Issue:4

    Topics: Amygdala; Animals; Aromatase Inhibitors; Autonomic Nervous System; Blood Pressure; Brain Chemistry; Estradiol; Estrogen Antagonists; Estrogens; Excitatory Amino Acid Antagonists; Fulvestrant; Heart Rate; Infarction, Middle Cerebral Artery; Injections, Intraventricular; Letrozole; Male; Microdialysis; Nitriles; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Synaptic Transmission; Testosterone; Triazoles

2005
Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis.
    The Journal of endocrinology, 2006, Volume: 188, Issue:2

    Topics: Animals; Apoptosis; Aromatase Inhibitors; Cell Division; Cell Line; Chondrocytes; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Letrozole; Metatarsal Bones; Nitriles; Rats; Triazoles

2006
Clinically occult cutaneous metastases.
    Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:6

    Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing

2006
Aromatase and breast cancer.
    The Journal of steroid biochemistry and molecular biology, 2006, Volume: 102, Issue:1-5

    Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2006
Progesterone, but not luteal estrogen, is required for the establishment of pregnancy in the new world monkey Cebus apella.
    American journal of primatology, 2007, Volume: 69, Issue:10

    Topics: Animals; Aromatase Inhibitors; Cebus; Embryo Implantation; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Letrozole; Luteal Phase; Male; Mifepristone; Nitriles; Pregnancy; Pregnancy Rate; Pregnancy, Animal; Progesterone; Triazoles

2007
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:8

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles

2007
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
    Biochemical pharmacology, 2008, Jul-15, Volume: 76, Issue:2

    Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Cell Line, Tumor; Coumarins; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Genes, Reporter; Genistein; Humans; Letrozole; Ligands; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; Tamoxifen; Thiazoles; Transfection; Triazoles

2008
Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus.
    Hippocampus, 2009, Volume: 19, Issue:8

    Topics: Animals; Animals, Newborn; Aromatase Inhibitors; Cells, Cultured; Cholesterol; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Hippocampus; In Vitro Techniques; Letrozole; Male; Microfilament Proteins; Nerve Tissue Proteins; Neurons; Nitriles; Phosphoproteins; Rats; Rats, Wistar; Synapses; Synaptophysin; Triazoles

2009
Androgen- and estrogen-independent regulation of copulatory behavior following castration in male B6D2F1 mice.
    Hormones and behavior, 2009, Volume: 56, Issue:2

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Animals; Aromatase; Aromatase Inhibitors; Copulation; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Flutamide; Fulvestrant; Letrozole; Male; Mating Preference, Animal; Mice; Nitriles; Orchiectomy; Preoptic Area; Receptors, Androgen; RNA, Messenger; Septal Nuclei; Triazoles

2009
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
    Anticancer research, 2009, Volume: 29, Issue:6

    Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured

2009
Long-term potentiation in the rat medial vestibular nuclei depends on locally synthesized 17beta-estradiol.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2009, Aug-26, Volume: 29, Issue:34

    Topics: Animals; Animals, Newborn; Aromatase Inhibitors; Bicuculline; Biophysics; Drug Interactions; Electric Stimulation; Estradiol; Estrogen Antagonists; Excitatory Amino Acid Antagonists; Fulvestrant; GABA Antagonists; In Vitro Techniques; Letrozole; Long-Term Potentiation; Male; Nitriles; Quinoxalines; Rats; Rats, Wistar; Triazoles; Valine; Vestibular Nuclei

2009
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms.
    International journal of cancer, 2010, Oct-15, Volume: 127, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Mice, Transgenic; Nitriles; Ovariectomy; Triazoles; Wnt1 Protein

2010
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
    Cancer research, 2011, Dec-15, Volume: 71, Issue:24

    Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oligonucleotide Array Sequence Analysis; Pyrazoles; Receptor, IGF Type 1; Receptor, Insulin; Tamoxifen; Triazines; Triazoles; Xenograft Model Antitumor Assays

2011
17β-Estradiol regulates cyclin A1 and cyclin B1 gene expression in adult rat seminiferous tubules.
    Journal of molecular endocrinology, 2012, Volume: 48, Issue:2

    Topics: Animals; Aromatase Inhibitors; Cyclin A1; Cyclin B1; Estradiol; Estrogen Antagonists; Fulvestrant; Gene Expression; Letrozole; Male; Nitriles; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Seminiferous Tubules; Spermatogenesis; Triazoles

2012
The chondroprotective effects of dehydroepiandrosterone probably exerted by its conversion to estradiol.
    The Journal of steroid biochemistry and molecular biology, 2013, Volume: 134

    Topics: Adjuvants, Immunologic; Animals; Aromatase Inhibitors; Cartilage; Cells, Cultured; Chondrocytes; Dehydroepiandrosterone; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Letrozole; Matrix Metalloproteinase 13; Matrix Metalloproteinase 3; Nitriles; Osteoarthritis; Rabbits; Tissue Inhibitor of Metalloproteinase-1; Triazoles

2013
Increased testicular Sertoli cell population induced by an estrogen receptor antagonist.
    Molecular and cellular endocrinology, 2013, Feb-05, Volume: 366, Issue:1

    Topics: Animals; Aromatase; Cell Count; Estradiol; Estrogen Antagonists; Fulvestrant; Letrozole; Male; Nitriles; Pituitary Hormones; Receptors, Estrogen; Sertoli Cells; Steroids; Sus scrofa; Triazoles

2013
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Cancer research, 2013, Jun-15, Volume: 73, Issue:12

    Topics: Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cohort Studies; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glial Cell Line-Derived Neurotrophic Factor; Humans; Kaplan-Meier Estimate; Letrozole; MCF-7 Cells; Middle Aged; Nitriles; Oligonucleotide Array Sequence Analysis; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Triazoles

2013
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
    Gynecologic and obstetric investigation, 2015, Volume: 80, Issue:1

    Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles

2015
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    International journal of oncology, 2015, Volume: 46, Issue:4

    Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Tamoxifen; Triazoles

2015
Steroid regulation of early postnatal development in the corpus epididymidis of pigs.
    The Journal of endocrinology, 2015, Volume: 225, Issue:3

    Topics: Androgen Receptor Antagonists; Animals; Aromatase; Aromatase Inhibitors; Blood-Testis Barrier; Epididymis; Estradiol; Estrogen Receptor Antagonists; Flutamide; Fulvestrant; Letrozole; Male; Microscopy, Electron, Transmission; Nitriles; Protein Isoforms; Receptors, Androgen; Receptors, Estrogen; Receptors, G-Protein-Coupled; Sexual Development; Signal Transduction; Sus scrofa; Tight Junctions; Triazoles

2015
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
    Oncotarget, 2015, Apr-20, Volume: 6, Issue:11

    Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Letrozole; MAP Kinase Signaling System; Mice; Mice, Nude; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Nitriles; Postmenopause; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Transcription, Genetic; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays; Zoledronic Acid

2015
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
    Oncology, 2015, Volume: 89, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles

2015
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
    Nature communications, 2016, Feb-09, Volume: 7

    Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles

2016
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
    The oncologist, 2017, Volume: 22, Issue:1

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles

2017
[Two Cases of Lung Metastasis from Breast Cancer Successfully Treated with Endocrine Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Letrozole; Lung Neoplasms; Nitriles; Treatment Outcome; Triazoles

2016
Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 08-01, Volume: 28, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Estradiol; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Letrozole; Male; Neoplasms, Multiple Primary; Nitriles; Prostatic Neoplasms; Tamoxifen; Triazoles

2017
Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jul-01, Volume: 28, Issue:suppl_4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Medical Oncology; Nitriles; Piperazines; Pyridines; Triazoles

2017
Treatment satisfaction in women receiving palbociclib combination therapies for advanced/metastatic breast cancer.
    Future oncology (London, England), 2019, Volume: 15, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Sectional Studies; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Patient Satisfaction; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Surveys and Questionnaires; Treatment Outcome

2019
Low-dose environmental endocrine disruptors, increase aromatase activity, estradiol biosynthesis and cell proliferation in human breast cells.
    Molecular and cellular endocrinology, 2019, 04-15, Volume: 486

    Topics: Aromatase; Breast; Cell Line, Tumor; Cell Proliferation; Endocrine Disruptors; Estradiol; Female; Fulvestrant; Humans; Letrozole; Receptors, Estrogen; RNA, Messenger; Testosterone

2019
Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Breast cancer research and treatment, 2019, Volume: 176, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Pyridines; Retrospective Studies; Treatment Outcome; Young Adult

2019
Are testicular cortisol and WISP2 involved in estrogen-regulated Sertoli cell proliferation?
    Animal reproduction science, 2019, Volume: 207

    Topics: Animals; CCN Intercellular Signaling Proteins; Cell Proliferation; Dexamethasone; Estrogens; Fulvestrant; Gene Expression; Hydrocortisone; Letrozole; Male; Sertoli Cells; Sex Differentiation; Spermatozoa; Swine; Testis

2019
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
    Breast cancer research and treatment, 2020, Volume: 183, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Drug Administration Schedule; Estrogens; Fatigue; Febrile Neutropenia; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Mucositis; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Estrogen; Thrombocytopenia

2020
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
    Breast cancer research : BCR, 2020, 09-14, Volume: 22, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Prospective Studies; Pyridines; Receptor, ErbB-2; Survival Rate; Tamoxifen; Thymidine Kinase

2020
The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer.
    Current oncology (Toronto, Ont.), 2022, 03-07, Volume: 29, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Piperazines; Progression-Free Survival; Pyridines; Retrospective Studies

2022
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
    The oncologist, 2022, 03-28, Volume: 27, Issue:Suppl 1

    Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Letrozole; Thiazoles

2022
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
    BMC cancer, 2022, May-07, Volume: 22, Issue:1

    Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; Letrozole; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Retrospective Studies

2022
Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Letrozole; Patient-Centered Care; Pharmacies; Protein Kinase Inhibitors; Retrospective Studies

2023
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.
    The oncologist, 2022, 08-05, Volume: 27, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Female; Fulvestrant; Humans; Letrozole; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone

2022
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
    Chinese medical journal, 2022, Jul-20, Volume: 135, Issue:14

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene

2022
Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
    Breast cancer research and treatment, 2022, Volume: 196, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Receptor, ErbB-2; Retrospective Studies; TOR Serine-Threonine Kinases

2022
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
    International journal of molecular sciences, 2022, Sep-21, Volume: 23, Issue:19

    Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen

2022
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 05-01, Volume: 29, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; Genomics; Humans; Letrozole; Receptor, ErbB-2

2023